Results of Vaccine Trial
According to The Street, Johnson & Johnson has made a big announcement that they plan to release more than a billion doses of the coronavirus vaccine next year. This will happen if the regulatory agencies in the United States approve the vaccine after successful non-human testing.
A representative from Johnson & Johnson Company released a statement about their vaccine demonstrating great performance in earlier trials. The vaccine is now being tested on volunteers from the United States and Belgium.
Earlier study, which was supported by the US government, showed that all vaccinated monkeys that were protected from the COVID-19. What's more, the vaccine helped induce a strong immune response to the disease with a help of just one dose when tested on monkeys.
The Reaction of Market
After the details of the research were published, shares of Johnson & Johnson gained 3% during the premarket trade. Nevertheless, the opening of the main trading session did not reflect the growth of shares. At the moment, they are trading at the opening price, with a slight fluctuation of up and down.
Successful tests set the long-run trend for the stock price to rise. On the contrary, any negative results in the research immediately start a downfall trend for the shares. The company intends to continue with human trials, and will release more than one billion doses of the vaccine in 2021 upon receiving US regulatory approval.